The U.S. Food and Drug Administration (FDA) has extended the approval of Amvuttra (vutrisiran) to adults with cardiomyopathy (heart…
Articles by Margarida Maia, PhD
Wainzua (eplontersen)Â is now approved in the European Union (EU) for treating adults with early-stage familial amyloid polyneuropathy (FAP). With…
Alnylam Pharmaceuticals is planning to launch a Phase 3 clinical trial toward the end of this year to test…
Throughout March — Amyloidosis Awareness Month — the Amyloidosis Foundation is inviting the public to join its “Light the…
Examining small samples of tissue from the skin and the salivary glands, those that produce saliva, increases the chances of…
A report on a 64-year-old man with familial amyloid polyneuropathy (FAP) may be the first to describe…
Problems with memory and problem-solving in people with hereditary transthyretin amyloidosis (ATTRv), a group of diseases that includes familial…
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to AT-02, Attralus’ investigational candidate for…
Diflunisal is used off-label to treat familial amyloid polyneuropathy (FAP), but it may be as safe and effective as…
Applying a fluorescent green tracer called AMDX-9101 during a routine eye exam may enable the detection of the toxic transthyretin…